IN2012DN00857A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00857A
IN2012DN00857A IN857DEN2012A IN2012DN00857A IN 2012DN00857 A IN2012DN00857 A IN 2012DN00857A IN 857DEN2012 A IN857DEN2012 A IN 857DEN2012A IN 2012DN00857 A IN2012DN00857 A IN 2012DN00857A
Authority
IN
India
Prior art keywords
pth
excellent safety
drug
achievement
inhibiting
Prior art date
Application number
Other languages
English (en)
Inventor
Shinichiro Shirae
Yasuo Nakamura
Yuiko Masunaga
Yoshihide Nozaki
Nobuyuki Kobayashi
Tatsuhiko Kuroda
Hiroki Kato
Masashi Serada
Kazuyoshi Hori
Original Assignee
Asahi Kasei Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43732444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN00857(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Asahi Kasei Pharma Corp filed Critical Asahi Kasei Pharma Corp
Publication of IN2012DN00857A publication Critical patent/IN2012DN00857A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
IN857DEN2012 2009-09-09 2010-09-08 IN2012DN00857A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009208039 2009-09-09
PCT/JP2010/065379 WO2011030774A1 (fr) 2009-09-09 2010-09-08 Agent thérapeutique/prophylactique contenant de la parathormone (pth) pour l'ostéoporose, caractérisé en ce que la pth est administrée une fois par semaine selon une dose unitaire de 100 à 200 unités

Publications (1)

Publication Number Publication Date
IN2012DN00857A true IN2012DN00857A (fr) 2015-07-10

Family

ID=43732444

Family Applications (1)

Application Number Title Priority Date Filing Date
IN857DEN2012 IN2012DN00857A (fr) 2009-09-09 2010-09-08

Country Status (17)

Country Link
US (3) US20120252729A1 (fr)
EP (3) EP2476429B1 (fr)
JP (13) JPWO2011030774A1 (fr)
KR (8) KR102335703B1 (fr)
CN (2) CN103893746A (fr)
AU (1) AU2010293488B2 (fr)
BR (1) BR112012003511A2 (fr)
CA (1) CA2772656A1 (fr)
ES (3) ES2843649T3 (fr)
HK (1) HK1168284A1 (fr)
IL (1) IL217854A (fr)
IN (1) IN2012DN00857A (fr)
MX (1) MX335951B (fr)
NZ (2) NZ598370A (fr)
RU (1) RU2564894C2 (fr)
WO (1) WO2011030774A1 (fr)
ZA (1) ZA201201720B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2616004T3 (es) * 2009-11-18 2017-06-09 Asahi Kasei Pharma Corporation Agente profiláctico y/o agente terapéutico y/o agente supresor de exacerbación para osteortritis de rodilla humana
JP6235219B2 (ja) * 2013-03-21 2017-11-22 旭化成ファーマ株式会社 脊椎椎体間固定術後の骨癒合促進剤
US10394953B2 (en) 2015-07-17 2019-08-27 Facebook, Inc. Meme detection in digital chatter analysis
JP2020506926A (ja) * 2017-02-01 2020-03-05 ザ・ジョンズ・ホプキンス・ユニバーシティ 副甲状腺ホルモンと変性椎間板疾患の再生
JP2019060866A (ja) * 2017-09-22 2019-04-18 旭化成ファーマ株式会社 液状医薬組成物の体内動態を予測する方法
CA3075984A1 (fr) * 2017-09-22 2019-03-28 Asahi Kasei Pharma Corporation Composition pharmaceutique liquide contenant de la teriparatide presentant d'excellentes proprietes pharmacocinetiques et/ou d'innocuite
WO2019059302A1 (fr) * 2017-09-22 2019-03-28 旭化成ファーマ株式会社 Composition pharmaceutique liquide contenant du tériparatide ayant une excellente stabilité
JP7080487B2 (ja) 2018-09-26 2022-06-06 東陽建設工機株式会社 鉄筋曲げ方法
CA3101326C (fr) 2018-10-29 2023-08-01 Asahi Kasei Pharma Corporation Methode de prevention ou de traitement de l'osteoporose caracterisee par l'administration de teriparatide ou d'un sel connexe a frequence de deux fois par semaine

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2505812B2 (ja) 1987-07-10 1996-06-12 旭化成工業株式会社 ｈ―ＰＴＨ（１―３４）凍結乾燥組成物
JP2662842B2 (ja) 1991-12-09 1997-10-15 旭化成工業株式会社 パラサイロイドホルモンの安定化組成物
JPH0873376A (ja) * 1994-09-07 1996-03-19 Asahi Chem Ind Co Ltd 骨粗鬆症治療薬
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
MY120063A (en) * 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
AR033639A1 (es) 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
US6756480B2 (en) * 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
IL153678A0 (en) 2000-06-30 2003-07-06 Suntory Ltd A pharmaceutical component comprising a human parathyroid hormone
JP5042419B2 (ja) * 2001-08-15 2012-10-03 旭化成ファーマ株式会社 骨形成促進剤および骨形成促進組成物
JP4931306B2 (ja) 2001-09-27 2012-05-16 旭化成ファーマ株式会社 骨形成を安全に促進させる医薬複合剤
EP1643978A1 (fr) * 2003-07-04 2006-04-12 Nycomed Danmark A/S Compositions pharmaceutiques contenant une hormone parathyroide (pth) administrees par voie orale
EP1741441A4 (fr) * 2004-04-26 2010-03-03 Ono Pharmaceutical Co Agent densifiant les os caracterise en ce qu'il utilise un inhibiteur de cathepsine k avec une pth
CN101151048A (zh) * 2004-05-10 2008-03-26 纳斯泰克制药公司 增强甲状旁腺激素粘膜递送的组合物和方法
JP2006241098A (ja) * 2005-03-04 2006-09-14 Univ Kurume 骨量減少症の予防または治療薬
WO2007092622A2 (fr) * 2006-02-09 2007-08-16 Biomimetic Therapeutics, Inc. Compositions et méthodes pour le traitement d'os
DE102006043846A1 (de) * 2006-03-14 2007-09-20 Claudia Zours Wirbelsäulenorthesen
WO2007106597A2 (fr) * 2006-03-15 2007-09-20 Alza Corporation Appareil et procede d'administration transdermique d'agents hormonaux parathyroidiens destines a traiter ou prevenir l'osteopenie
CN101274961A (zh) * 2006-03-30 2008-10-01 天津医科大学 重组人甲状旁腺素相关蛋白
CN101125201A (zh) * 2006-08-17 2008-02-20 石家庄欧意药业有限公司 治疗骨质疏松症或防治由于骨质疏松而导致的骨折的药物组合物及其应用
CN101307105B (zh) * 2008-04-28 2012-08-29 中国药科大学 一种能串联表达和同步酸水解释放的人甲状旁腺素1-34肽类似物及其制备方法和应用

Also Published As

Publication number Publication date
JP2019023234A (ja) 2019-02-14
IL217854A0 (en) 2012-03-29
MX2012002681A (es) 2012-04-19
JP2017105858A (ja) 2017-06-15
KR20120067336A (ko) 2012-06-25
EP2682125B1 (fr) 2020-11-04
ES2843649T3 (es) 2021-07-20
EP2476429A1 (fr) 2012-07-18
CN103893746A (zh) 2014-07-02
KR20200115673A (ko) 2020-10-07
MX335951B (es) 2016-01-04
AU2010293488B2 (en) 2014-11-27
RU2564894C2 (ru) 2015-10-10
JP6275900B2 (ja) 2018-02-07
JP2018024710A (ja) 2018-02-15
JP6150846B2 (ja) 2017-06-21
KR20170089017A (ko) 2017-08-02
JP2016130261A (ja) 2016-07-21
JP2017105861A (ja) 2017-06-15
AU2010293488A1 (en) 2012-03-29
KR102424644B1 (ko) 2022-07-25
EP2682124B1 (fr) 2018-02-28
BR112012003511A2 (pt) 2019-09-24
JP6301524B2 (ja) 2018-03-28
NZ598370A (en) 2014-04-30
EP2682124A1 (fr) 2014-01-08
RU2012108635A (ru) 2013-10-20
KR20210040171A (ko) 2021-04-12
JP2017105862A (ja) 2017-06-15
JP2015157854A (ja) 2015-09-03
US20140249084A1 (en) 2014-09-04
JPWO2011030774A1 (ja) 2013-02-07
JP2017105863A (ja) 2017-06-15
EP2476429A4 (fr) 2013-02-27
WO2011030774A1 (fr) 2011-03-17
JP6198346B2 (ja) 2017-09-20
KR20190095552A (ko) 2019-08-14
JP6274634B2 (ja) 2018-02-07
ES2663322T3 (es) 2018-04-12
JP2017105859A (ja) 2017-06-15
ZA201201720B (en) 2012-11-28
JP6043008B2 (ja) 2016-12-14
IL217854A (en) 2016-08-31
KR102335703B1 (ko) 2021-12-07
KR20150021590A (ko) 2015-03-02
JP2017105860A (ja) 2017-06-15
CN102470164B (zh) 2014-04-09
ES2662018T3 (es) 2018-04-05
US20120252729A1 (en) 2012-10-04
CN102470164A (zh) 2012-05-23
JP2015147813A (ja) 2015-08-20
EP2682125A1 (fr) 2014-01-08
NZ617397A (en) 2015-02-27
US20140357560A1 (en) 2014-12-04
KR20170089018A (ko) 2017-08-02
KR20140130754A (ko) 2014-11-11
JP2017061511A (ja) 2017-03-30
JP6522715B2 (ja) 2019-05-29
CA2772656A1 (fr) 2011-03-17
EP2476429B1 (fr) 2018-03-07
HK1168284A1 (en) 2012-12-28

Similar Documents

Publication Publication Date Title
IN2012DN00857A (fr)
TN2012000143A1 (en) Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
MY168791A (en) Carbamate compounds and of making and using same
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
DE502005005636D1 (en) Spirocyclische cyclohexan-derivate
MX2013013809A (es) Dispositivos expandibles con revestimiento de una composicion de paclitaxel.
MX2014008021A (es) Compuestos de fenil carbamato para usarse en aliviar o tratar el dolor.
EP2490700A4 (fr) Composition de soin externe pour la peau comprenant un sel et du sucre en tant que principes actifs pour prévenir et traiter la vaginose et utilisation de cette composition
MX369117B (es) Antagonistas del receptor ep4 para el tratamiento de cancer.
MX356704B (es) Combinación.
SA113340494B1 (ar) تركيبة لعلاج اضطرابات أيضية
MX2013013808A (es) Dispositivos expandibles con revestimiento de una composicion de rapamicina.
IN2014DN09779A (fr)
MX2012003892A (es) Agente preventivo y/o agente terapeutico y/o agente supresivo del agravamiento para la artritis humana deformante.
WO2011089531A3 (fr) Effets de l'association de la vitamine k2 et de la vitamine d3 dans la consolidation d'une fracture osseuse
MX2014015096A (es) Alimento para crustaceos.
MX2015012666A (es) Preparacion de complejo que incluye valsartan y rosuvastatina calcica y metodo de fabricacion para el mismo.
MX2014013491A (es) Metodos para mantener, tratar o mejorar la funcion cognitiva.
WO2012011673A3 (fr) Compositions pharmaceutiques comprenant l'hespéridine comme ingrédient actif pour favoriser la différenciation ou le renouvellement des cellules musculaires
UA56460U (ru) Способ лечения травматических повреждений периферического нерва
UA53407U (ru) Способ профилактики и лечения перенашевания беременности
MX2012012712A (es) Composicion farmaceutica para uso en el tratamiento o prevencion de una o varias enfermedaes inflamatorias y/o enfermedades autoinmunitarias.
UA78297U (ru) Способ иммунокоррекции у больных с переломами проксимального отдела бедра на фоне абдоминального ожирения
MD10Z (ro) Metodă de tratament al pielonefritei gestaţionale
UA92302C2 (ru) Лекарственное средство для терапии злокачественных опухолей и способ лечения злокачественных опухолей с его использованием